In July 2023, the Centers for Medicare & Medicaid services (CMS) overhauled its oncology value-based care model, instituting the Enhancing Oncology Model (EOM) as a replacement for the Oncology Care Model (OCM) that expired in 2022. Only 41 community oncology practices participated in EOM’s first cohort—a significant decrease from the 122 participants under OCM. In response, CMS created a second EOM application round and instituted several reforms to drive participation and improve the model's effectiveness.
The second round of EOM applications closed on September 16, 2024, and came with several enhancements, including:
Thus far, EOM has led to modest changes in participating community oncology practices (Figure 1); in part this is due to many EOM participants implementing changes during their prior experience in OCM.
As the second round of EOM progresses, MAI anticipates additional practices joining the initiative. However, the full scope of patient and provider outcomes remains to be seen.
For deeper insights into EOM’s impact on community oncology practices and manufacturer considerations, explore our 2024 Community Oncology Report.
Please don’t hesitate to reach out if you have any questions, I would love to hear from you! I can be reached at asheth@hmpglobal.com.
As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.
Daniel BuchenbergerIn the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.
Lee BlansettBispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Chris Van Denburg